Artificial intelligence and machine learning companies develop software, algorithms and computational platforms that analyse biological data, automate workflows and accelerate scientific discovery. These technologies are increasingly used across drug discovery, diagnostics, genomics and healthcare research.
This category includes companies working on:
Browse 243 UK AI and machine learning companies below.
Computational chemistry software and consulting for small molecule discovery
Cresset Biomolecular Discovery is a UK software and consulting company providing computational chemistry solutions for small molecule drug discovery and design. Its patented field technology evaluates molecules using surface properties rather than 2D structural similarity, enabling virtual screening, scaffold hopping,…
AI-designed extended-expression RNA therapeutics for cardio-metabolic disease
ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months. Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling…
Diverse oncology datasets for AI-driven precision medicine research
CureCollect is a life science data company sourcing multimodal oncology datasets for precision medicine and artificial intelligence research. It collaborates with hospitals and laboratories to assemble pathology images, genomic and transcriptomic data, longitudinal clinical records and treatment outcomes from diverse…
AI-powered drug design engine built on AlphaFold technology
Isomorphic Labs is an artificial intelligence company applying frontier AI to drug discovery, built on and beyond the Nobel Prize-winning AlphaFold protein structure prediction system developed at Google DeepMind. Its proprietary drug design engine spans target identification, molecular design, and binding prediction…
AI-designed enzymes for enzymatic recycling of plastics and textiles
Epoch Biodesign is a London-based industrial biotech developing AI-engineered enzymes for the biorecycling of mixed plastics and textiles. The company's platform uses machine learning to design enzymes that deconstruct waste materials at the molecular level, recovering high-purity chemical building blocks for…
Fragment and structure-based drug discovery services
Vernalis (R&D) is a Cambridge-based contract drug discovery organisation specialising in fragment-based and structure-based drug discovery. The company integrates structural biology, biophysics, NMR spectroscopy, DNA-encoded library screening, medicinal chemistry, and computational approaches to identify and progress…
CASPAROV AI platform for targets in heterogeneous cancers
Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…
AI platform targeting chromosomal instability across cancer
Tailor Bio is a Cambridge-based biotechnology company developing an AI-driven precision medicine platform for cancers with chromosomal instability, a genomic phenomenon present in over 80% of all cancers. Founded from research originating at the Cancer Research UK Cambridge Institute, the company develops both…
AI-generated virtual patients for medical device testing
adsilico is a University of Leeds spin-out developing computational models for preclinical medical device research. It combines generative AI with anonymised clinical imaging to create synthetic patient anatomies, then uses physics-based simulations to investigate how implantable devices perform across diverse…
AI imaging platform for lung and heart disease clinical trials
Qureight is a technology-driven imaging contract research organisation providing clinical data curation and AI-powered image analysis services to pharmaceutical and biotech companies. Its proprietary platform integrates CT imaging, biomarkers, and clinical metadata from complex respiratory and cardiovascular diseases,…
AI platform for drug target safety assessment and toxicity prediction
SableBio is a software company providing an AI-driven target safety intelligence platform for drug discovery teams. The platform analyses large volumes of biomedical data, including unstructured scientific literature, to quantify and prioritise toxicology risks associated with drug targets earlier in the development…
RNA trans-splicing gene therapies for aggressive cancers
Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…
AI-driven rescue and development of failed drug candidates
Ignota Labs is a biotechnology company that identifies, in-licenses and redevelops drug candidates that have failed clinical development due to toxicity. Using deep learning applied to cheminformatics and bioinformatics data, the company resolves the mechanistic basis of safety failures and makes targeted chemical…
AI-designed combination therapies for cancer
Big Picture Bio is a preclinical biotechnology company designing combination therapies for cancer. Its generative model simulates how tumours, immune cells and surrounding tissue interact, and is used to predict which drug combinations, and which sequences of treatment, are most likely to suppress resistant cancer…
RNA-based gene control systems for safer cell and gene therapies
Concinnity Genetics is a biotechnology company developing RNA-based control systems that enable precise regulation of gene therapies after administration. Its technology allows therapeutic gene expression to be modulated or reduced in response to side effects or clinical need, addressing a fundamental safety…
Mitochondrial disease drug discovery subsidiary of Astellas Pharma
Astellas Engineered Small Molecules U.K. is a Cambridge-based drug discovery subsidiary of Astellas Pharma, operating as part of the company's Mitobridge Division alongside its US counterpart Mitobridge Inc. Originally founded as Nanna Therapeutics and acquired by Astellas in 2020, the entity applies a proprietary…
AI platform for drug target identification and discovery
BenevolentAI is a UK-founded biotech company that develops and applies AI and machine learning to accelerate drug discovery. Its platform integrates knowledge graphs, proprietary ontologies, and large language models to identify novel therapeutic targets and design small molecule candidates across multiple disease…
Quantum-informed computational design of covalent drug candidates
Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines. Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug…
Computational chemistry and data informatics for drug discovery
NovaData Solutions is a contract research organisation providing computational chemistry, molecular modelling, and data informatics services to pharmaceutical and biotechnology clients. Its capabilities span the early drug discovery workflow, including target validation, hit identification, lead optimisation, and…
AI-driven protein interaction modelling for peptide drug discovery
Xenos Bio is developing a computational platform that uses physics-based algorithms integrated with machine learning to predict protein-protein interactions and identify binding motifs within functional protein domains. Its software is deployed for rational peptide library construction, delivering enhanced hit…